,

Metabolic syndrome increases risk of respiratory distress, death for hospitalized COVID-19 patients

Metabolic syndrome increases risk of respiratory distress death for hospitalized COVID19 patients - سندرم متابولیک و کرونا

Patients hospitalized with COVID-19 who had a combination of high blood pressure, obesity, diabetes or other conditions associated with metabolic syndrome were at much higher risk of acute respiratory distress syndrome (ARDS) and death, according to an international study published in the medical journal JAMA Network Open.

The risk for developing ARDS, a life-threatening lung condition that causes low blood oxygen, grew progressively higher with each additional metabolic syndrome criteria present. The study, one of the largest to examine the link between metabolic syndrome and outcomes for COVID-19, examined records of more than 46,000 patients admitted in 181 hospitals across 26 countries.

Researchers from Tulane University, the Society of Critical Care Medicine and Mayo Clinic followed outcomes for patients hospitalized between mid-February 2020 to mid-February 2021 in the Discovery VIRUS: COVID-19 Registry. Researchers compared 5,069 patients (17.5%) with metabolic syndrome with 23,971 control patients (82.5%) without metabolic syndrome. They defined metabolic syndrome as having more than three of the following criteria: obesity, pre-diabetes or diabetes, hypertension and high cholesterol.

Patients with metabolic syndrome were 36% more likely to develop ARDS, almost 20% more likely to die in the hospital, more than 30% more likely to be admitted to an ICU and 45% more likely to require mechanical ventilation. Researchers calculated these risks after adjusting for race, age, sex, ethnicity, other comorbid conditions and hospital case volume.

Overall, slightly more than 20% of the patients with metabolic syndrome died in the hospital, 20% developed ARDS and almost half were admitted to the ICU. Approximately 16% of those without metabolic syndrome died, 12% developed ARDS and nearly 36% were admitted to the ICU.

Metabolic syndrome was significantly more common among patients with COVID-19 admitted to U.S. hospitals (18.8%) than those admitted to non-U.S. hospitals (8%). According to the Centers for Disease Control, more than a third of adults in the U.S. meet the criteria for metabolic syndrome, with some regions having a metabolic syndrome prevalence greater than 40%.

Release date: 22 December 2021
Source: Tulane University